Melanoma/Skin Cancer Detection and Prevention Month® (see related guidelines) 1 (1/1) | National Guideline Clearinghouse

Search | National Guideline Clearinghouse

Health Awareness Topics: May 2018

• Melanoma/Skin Cancer Detection and Prevention Month® (see related guidelines)

• GUIDELINE SUMMARY
 
• NGC:010264
 
• 2012 MAR (REVISED 2013 FEB)

Preoperative and pretreatment investigations for malignant melanoma.

CancerControl Alberta

Compare

• GUIDELINE SUMMARY
 
• NGC:010262
 
• 2011 FEB (REVISED 2013 FEB)

Optimal excision margins for primary cutaneous melanoma.

CancerControl Alberta

Compare

• GUIDELINE SUMMARY
 
• NGC:010672
 
• 1996 (REVISED 2014)

ACR Appropriateness Criteria® non-spine bone metastases.

American College of Radiology

Compare

• GUIDELINE SUMMARY
 
• NGC:010259
 
• 2010 MAY (REVISED 2013 FEB)

Management of in-transit disease of the limbs.

CancerControl Alberta

Compare

• GUIDELINE SUMMARY
 
• NGC:010817
 
• 2015 OCT 7

Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab.

National Institute for Health and Care Excellence (NICE)

Compare

• GUIDELINE SUMMARY
 
• NGC:010248
 
• 2012 MAR (REVISED 2013 FEB)

Biopsy of a suspicious pigmented lesion.

CancerControl Alberta

Compare

• GUIDELINE SUMMARY
 
• NGC:010901
 
• 2016 FEB 10

Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and over.

National Guideline Alliance

Compare

• GUIDELINE SUMMARY
 
• NGC:010571
 
• 2014 OCT

Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma.

National Institute for Health and Care Excellence (NICE)

Compare

• GUIDELINE SUMMARY
 
• NGC:010828
 
• 2015 NOV 11

VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions.

National Institute for Health and Care Excellence (NICE)

Compare

• GUIDELINE SUMMARY
 
• NGC:010783
 
• 2015 JUL 29

Melanoma: assessment and management.

National Guideline Alliance

Compare

• GUIDELINE SUMMARY
 
• NGC:010260
 
• 2010 MAY (REVISED 2013 FEB)

Management of resectable stage IV primary cutaneous melanoma without nodal disease.

CancerControl Alberta

Compare

• GUIDELINE SUMMARY
 
• NGC:010266
 
• 2011 FEB (REVISED 2013 FEB)

Referral and follow-up surveillance of cutaneous melanoma.

CancerControl Alberta

Compare

• GUIDELINE SUMMARY
 
• NGC:010882
 
• 2015 AUG

Systemic therapy for unresectable stage III or metastatic cutaneous melanoma.

CancerControl Alberta

Compare

• GUIDELINE SUMMARY
 
• NGC:009838
 
• 2013 MAR

Proton beam radiation therapy.

CancerControl Alberta

Compare

• GUIDELINE SUMMARY
 
• NGC:011023
 
• 2016 JUL

Final recommendation statement: skin cancer: screening.

U.S. Preventive Services Task Force

Compare

• GUIDELINE SUMMARY
 
• NGC:010860
 
• 2015 NOV 25

Pembrolizumab for advanced melanoma not previously treated with ipilimumab.

National Institute for Health and Care Excellence (NICE)

Compare

• EXPERT COMMENTARY
 

Importance of Quality Metrics for Providing High Quality Melanoma Care

By: Karl Y. Bilimoria, MD, MS

• GUIDELINE SUMMARY
 
• NGC:010377
 
• 2014 FEB

Adjuvant interferon for malignant melanoma.

CancerControl Alberta